The 2010 results were generally in line with expectations. The company's revenue in 2010 was 327 million yuan, a year-on-year decrease of 1.32%; net profit of 34 million yuan, basic earnings per share were 0.11 yuan, and basic earnings per share were -0.09 yuan after deduction. The company's overall performance basically met our expectations, and the results were reversed, but the profit achieved in 2010 was mainly achieved by non-recurring bank interest cuts. In 2011, the company's development will achieve a lightweight launch. The company has completed the relocation of the new factory area and is actively promoting the disposal of idle assets formed after the relocation in order to completely improve the company's financial situation by returning debts. Through continuous debt disposal, the company's remaining 334 million yuan of financial institution loans is expected to be fully repaid in 2011, and the lightweight launch ushered in a new stage of development. The pharmaceutical industry is booming. During the reporting period, the pharmaceutical industry achieved sales revenue of 127.2987 million yuan, an increase of 10.07% over the same period last year, and the pharmaceutical industry's gross margin continued to rise to 63.68%, indicating that high-margin Jintiange capsule products maintained a good growth trend. The pharmaceutical industry's main business revenue share continued to rise to 38.41%, and the profit share reached 78.74%. The pharmaceutical industry business was fully equipped to support the company's continuous development. Pharmaceutical commercial revenue continues to decline. During the reporting period, the pharmaceutical business achieved sales revenue of 154.6838 million yuan, down 12.34% from the same period last year, maintaining the year-on-year decline trend. Currently, the share of pharmaceutical commercial main business revenue has dropped to 47.48%. As a small-scale pharmaceutical distribution enterprise, Jinhua Pharmaceutical Chemical Glass has no competitive advantage in the current accelerated integration pattern of China's pharmaceutical distribution sector. In 2010, its gross margin level was 1.66%. It is expected that the pharmaceutical business revenue will continue to decline in the future. The hotel business may gradually get out of trouble. Jinhua International Hotel Co., Ltd. achieved operating income of 455.417 million yuan in 2010, an increase of 14.24% over the same period last year, and achieved operating profit of 18.8704 million yuan. After accounting for depreciation of fixed assets, a loss of 13.2196 million yuan was further reduced. Considering that the second phase of the hotel project will have a scale effect once it is put into use after several years of construction, we believe that the company's hotel business is showing a trend of gradually getting out of business difficulties. Profit forecast: Maintain the company's 2011 and 2012 EPS profit forecasts of 0.08 and 0.21 yuan, respectively, and maintain the “gain” rating for the company. Risk warning: Whether the debt settlement work can proceed smoothly; the progress of industrial development is lower than expected.